BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 26820213)

  • 1. [Current diagnosis and treatment of hyperprolactinemia].
    Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
    Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic evaluation of hyperprolactinemia.
    Biller BM
    J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prolactinoma].
    Glezer A; Bronstein MD
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approach to the Patient With Prolactinoma.
    Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.
    Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD
    Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical presentation of hyperprolactinemia.
    Luciano AA
    J Reprod Med; 1999 Dec; 44(12 Suppl):1085-90. PubMed ID: 10649815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GIANT PROLACTINOMA. A CASE REPORT.
    Šulavíková Z; Krásnik V
    Cesk Slov Oftalmol; 2023; 79(3):143-148. PubMed ID: 37344216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperprolactinemia unrelated to prolactinoma].
    Krysiak R; Okopień B
    Wiad Lek; 2014; 67(2 Pt 1):101-11. PubMed ID: 25764785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for the diagnosis and treatment of hyperprolactinemia.
    Biller BM; Luciano A; Crosignani PG; Molitch M; Olive D; Rebar R; Sanfilippo J; Webster J; Zacur H
    J Reprod Med; 1999 Dec; 44(12 Suppl):1075-84. PubMed ID: 10649814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprolactinemia and prolactinomas.
    Mancini T; Casanueva FF; Giustina A
    Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
    Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
    Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major depressive disorder induced by prolactinoma--a case report.
    Liao WT; Bai YM
    Gen Hosp Psychiatry; 2014; 36(1):125.e1-2. PubMed ID: 24182617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Simultaneous defect of visual fields and loss of libido--a coincidence?].
    Jenni S; Seiler R; Christ ER; Stettler C
    Praxis (Bern 1994); 2006 Dec; 95(49):1925-30. PubMed ID: 17212311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary production of prolactin and prolactin-suppressing drugs.
    Tansey MJ; Schlechte JA
    Lupus; 2001; 10(10):660-4. PubMed ID: 11721691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
    Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
    J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.